{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["251"],"submitter":["Koh JY"],"pubmed_abstract":["A dysregulated hyperinflammatory response is a key pathogenesis of severe COVID-19, but optimal immune modulator treatment has not been established. To evaluate the clinical effectiveness of double (glucocorticoids and tocilizumab) and triple (plus baricitinib) immune modulator therapy for severe COVID-19, a retrospective cohort study was conducted. For the immunologic investigation, a single-cell RNA sequencing analysis was performed in serially collected PBMCs and neutrophil specimens. Triple immune modulator therapy was a significant factor in a multivariable analysis for 30-day recovery. In the scRNA-seq analysis, type I and II IFN response-related pathways were suppressed by GC, and the IL-6-associated signature was additionally downregulated by TOC. Adding BAR to GC and TOC distinctl"],"journal":["Clinical immunology (Orlando, Fla.)"],"pagination":["109628"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10139747"],"repository":["biostudies-literature"],"pubmed_title":["Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19."],"pmcid":["PMC10139747"],"pubmed_authors":["Lee JS","Kang CI","Kim SH","Bae S","Ko JH","Peck KR","Huh K","Koh JY","Lim SY","Cho SY","Chung CR","Chung DR"],"additional_accession":[]},"is_claimable":false,"name":"Triple immune modulator therapy for aberrant hyperinflammatory responses in severe COVID-19.","description":"A dysregulated hyperinflammatory response is a key pathogenesis of severe COVID-19, but optimal immune modulator treatment has not been established. To evaluate the clinical effectiveness of double (glucocorticoids and tocilizumab) and triple (plus baricitinib) immune modulator therapy for severe COVID-19, a retrospective cohort study was conducted. For the immunologic investigation, a single-cell RNA sequencing analysis was performed in serially collected PBMCs and neutrophil specimens. Triple immune modulator therapy was a significant factor in a multivariable analysis for 30-day recovery. In the scRNA-seq analysis, type I and II IFN response-related pathways were suppressed by GC, and the IL-6-associated signature was additionally downregulated by TOC. Adding BAR to GC and TOC distinctl","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jun","modification":"2025-04-22T05:15:10.714Z","creation":"2025-02-19T02:26:24.123Z"},"accession":"S-EPMC10139747","cross_references":{"pubmed":["37119951"],"doi":["10.1016/j.clim.2023.109628"]}}